BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations
-
- Safoora Deihimi
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Avital Lev
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Michael Slifker
- Biostatistics and Bioinformatics Department, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Elena Shagisultanova
- Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Qifang Xu
- Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Kyungsuk Jung
- Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Namrata Vijayvergia
- Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Eric A. Ross
- Biostatistics and Bioinformatics Department, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Joanne Xiu
- Caris Life Science, Phoenix, AZ, USA
-
- Jeffrey Swensen
- Caris Life Science, Phoenix, AZ, USA
-
- Zoran Gatalica
- Caris Life Science, Phoenix, AZ, USA
-
- Mark Andrake
- Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Roland L. Dunbrack
- Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA
-
- Wafik S. El-Deiry
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, USA
書誌事項
- 公開日
- 2017-05-23
- DOI
-
- 10.18632/oncotarget.18098
- 公開者
- Impact Journals, LLC
収録刊行物
-
- Oncotarget
-
Oncotarget 8 (25), 39945-39962, 2017-05-23
Impact Journals, LLC
